The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis

BACKGROUND: The role of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) is not clear in early‐stage nonsmall‐cell lung cancer (NSCLC) patients. This meta‐analysis aims to compare the efficacy and safety of EGFR‐TKIs as adjuvant therapy with chemotherapy or placebo in...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Thorac Cancer
Prif Awduron: Lin, Chutong, Hu, Fengling, Chu, Hongling, Ren, Peng, Ma, Shanwu, Wang, Jingdi, Bai, Jie, Han, Xuan, Ma, Shaohua
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons Australia, Ltd 2021
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8017245/
https://ncbi.nlm.nih.gov/pubmed/33660941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13874
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg